Dasatinib is a drug developed for the treatment of leukemias, and it exerts its antitumoral activity by inhibition of SCR/ABL1 kinases, and by inhibiting the BCL-ABL1 fusion protein, the driving oncogene of chronic myeloid leukemia15,16. The gene discussed is ABL1; the disease is leukemia.